SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in a fireside chat at the 2024 ...

Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024: Watertown, Massachusetts Tuesday, November 12, 2024, 13:00 ...

Rates of survival after out-of-hospital cardiac arrest (OHCA) have not fully bounced back since the COVID-19 pandemic, ...

All patients who have had a heart attack are typically treated using beta blockers. According to a recent study, this drug is unlikely to be needed for those heart patients who have a normal pumping ...

Transcatheter implantation of the Ventura interatrial shunt is safe but does not lead to improved clinical outcomes in patients with heart failure (HF) and preserved left ventricular ejection fraction ...

Cardiac resynchronization therapy (CRT) is considered a beneficial and disease-modifying treatment in appropriately selected heart failure (HF) patients. It reduces morbidity and mortality, reverses ...

In a trial that many are calling landmark, transcatheter aortic valve replacement had better outcomes than surveillance for ...

Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Na ...

About the APEX Phase 2 Clinical Trial for TX45 in Pulmonary Hypertension with HFpEF TX45 is being evaluated in the APEX Phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary ...